
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00.
Shares of Ultragenyx Pharmaceutical are trading up 2.9% over the last 24 hours, at $53.30 per share.

Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00.
Shares of Ultragenyx Pharmaceutical are trading up 2.9% over the last 24 hours, at $53.30 per share.